CPP mediated insulin delivery: Current status and promising future

Current Pharmaceutical Biotechnology

Volumn 15, Issue 3, 2014, Pages 240-255

  Liu, Ergang ^a,b   Sheng, Jianyong ^c   Ye, Junxiao ^a,b   Wang, Yaping ^b   Gong, Junbo ^a   Yang, Victor C ^b,d,e   Wang, Jianxin ^c   He, Huining ^b,c  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

^e Seoul National University   (South Korea)

Author keywords

Bioavailability; Cell penetrating peptide; Insulin; Nonparenteral administration

Indexed keywords

CELL PENETRATING PEPTIDE; INSULIN; MORPHOLINO OLIGONUCLEOTIDE; NANOPARTICLE; PENETRATIN; POLYMER; SOLID LIPID NANOPARTICLE; TRANSACTIVATOR PROTEIN; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA INTERFERON; BETA CYCLODEXTRIN; CHYMOTRYPSIN; CHYMOTRYPSIN A; DEXTRAN; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; LEUPRORELIN; LIPID NANOPARTICLE; LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE; OLIGOARGININE; POLYARGININE; PROTAMINE; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ABSORPTION; ARTICLE; BIOAVAILABILITY; CHEMICAL STRUCTURE; CONJUGATE; DIABETES MELLITUS; DRUG DISTRIBUTION; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; HYDROGEN BOND; IMMUNOGENICITY; INTERNALIZATION; MICRONEEDLE; NONHUMAN; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING AND TRANSPORT; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; HYDROPHILICITY; INSULIN RESISTANCE; PEPTIDE LIBRARY; POSITRON EMISSION TOMOGRAPHY; RETICULOENDOTHELIAL SYSTEM; SURFACE PLASMON RESONANCE; ANIMAL; CHEMISTRY;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84907342376     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140813125840     Document Type: Article

References (102)

1. Singh, S.; Patel, D.; Patel, N.R.; Kumar, K.; Gautam, M.K. Insulin oral delivery may be possible. Int. J. Pharm. Prof. Res., 2010, 1(1), 46-51.
2. Tahtat, D.; Mahlous, M.; Benamer, S.; Khodja, A. N.; Oussedik- Oumehdi, H.; Laraba-Djebari, F. Oral delivery of insulin from alginate/chitosan crosslinked by glutaraldehyde. Int. J. Biol. Macromol., 2013, 58, 160-168.
3. Shinde, P.V. Novel carrier systems for oral delivery of insulin. Asian J. Pharm. Tech. Innov., 2013, 1(02), 01-09.
4. Khafagy, E.S.; Morishita, M.; Onuki, Y.; Takayama, K. Current challenges in non-invasive insulin delivery systems: A comparative review. Adv. Drug. Delivery. Rev., 2007, 59(15), 1521-1546.
5. Arbit, E. The physiological rationale for oral insulin administration. Diabetes Technol. Ther., 2004, 6(4), 510-517.
6. Sonia, T.; Sharma, C.P. An overview of natural polymers for oral insulin delivery. Drug Discov. Today, 2012, 17(13), 784-792.
7. Harvey, M.; Cave, G.; Lahner, D.; Desmet, J.; Prince, G.; Hopgood, G. Insulin versus lipid emulsion in a rabbit model of severe propranolol toxicity: a pilot study. Crit. Care Res. Pract., 2011, article ID 361737.
8. Niu, M.; Lu, Y.; Hovgaard, L.; Wu, W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomedicine, 2011, 6, 1155-1166.
9. Trotta, M.; Carlotti, M.; Gallarate, M.; Zara, G.; Muntoni, E.; Battaglia, L. Insulin-loaded SLN prepared with the emulsion dilution technique: in vivo tracking of nanoparticles after oral administration to rats. J. Dispers. Sci. Technol., 2011, 32(7), 1041-1045.
10. Chaturvedi, K.; Ganguly, K.; Nadagouda, M.N.; Aminabhavi, T.M. Polymeric hydrogels for oral insulin delivery. J. Control. Release, 2013, 165(2), 129-138.
11. Shakeel, M.; Pathan D.N.; Ziyaurrrahman, A.; Akber, B.; Bushra, S. Microneedle as a novel drug delivery system: a review. Int. Res. J. Pharm., 2011, 2, 72-77.
12. Soltani-Arabshahi, R.; Wong, J.W.; Duffy, K.L.; Powell, D.L. Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatol., 2014, 150(1), 68-72.
13. Renukuntla, J.; Vadlapudi, A.D.; Patel, A.; Boddu, S.H.; Mitra, A.K. Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm., 2013, 447(1), 75-93.
14. Jose, S.; Fangueiro, J.; Smitha, J.; Cinu, T.; Chacko, A.; Premaletha, K.; Souto, E. Cross-linked chitosan microspheres for oral delivery of insulin: Taguchi design and in vivo testing. Colloids and Surfaces B: Biointerfaces, 2012, 92, 175-179.
15. MA, H.; LIU, Z.; Zheng, C.X. In vitro and in vivo evaluation of a novel oral insulin formulation1. Acta. Pharmacol. Sin., 2006, 27(10), 1382-1388.
16. Zhang, X.; Sun, M.; Zheng, A.; Cao, D.; Bi, Y.; Sun, J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci., 2012, 45(5), 632-638.
17. Degim, Z.; Degim, T.; Acartürk, F.; Erdogan, D.; Özogul, C.; Köksal, M. Rectal and vaginal administration of insulin-chitosan formulations: An experimental study in rabbits. J. Drug Target, 2005, 13(10), 563-572.
18. Elsayed, A.M. Oral Delivery of Insulin: Novel Approaches. 2012.
19. Sarmento, B.; Ribeiro, A.; Veiga, F.; Sampaio, P.; Neufeld, R.; Ferreira, D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res., 2007, 24(12), 2198-2206.
20. Sonaje, K.; Chen, Y.J.; Chen, H.L.; Wey, S.P.; Juang, J.H.; Nguyen, H.N.; Hsu, C.W.; Lin, K.J.; Sung, H.W. Enteric-coated capsules filled with freeze-dried chitosan/poly (γ-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials, 2010, 31(12), 3384-3394.
21. Su, F.Y.; Lin, K.J.; Sonaje, K.; Wey, S.P.; Yen, T.C.; Ho, Y.C.; Panda, N.; Chuang, E.Y.; Maiti, B.; Sung, H.W. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials, 2012, 33(9), 2801-2811.
22. Zhang, Z.; Lv, H.; Zhou, J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Die. Pharmazie. - An Int. J. Pharm. Sci, 2009, 64(9), 574-578.
23. Zhang, Z.H.; Zhang, Y.L.; Zhou, J.P.; Lv, H.X. Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int. J. Nanomedicine, 2012, 7, 3333-3339.
24. Sarko, D.; Beijer, B.; Boy, R.G.; Nothelfer, E.M.; Leotta, K.; Eisenhut, M.; Altmann, A.; Haberkorn, U.; Mier, W. The pharmacokinetics of cell-penetrating peptides. Mol. Pharm., 2010, 7(6), 2224-2231.
25. Koren, E.; Torchilin, V.P. Cell-penetrating peptides: Breaking through to the other side. Trends Mol. Med., 2012, 18(7), 385-393.
26. Milletti, F. Cell-penetrating peptides: Classes, origin, and current landscape. Drug Discov. Today, 2012, 17(15), 850-860.
27. Khafagy, E.S.; Morishita, M.; Isowa, K.; Imai, J.; Takayama, K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release, 2009, 133(2), 103-108.
28. Morishita, M.; Kamei, N.; Ehara, J.; Isowa, K.; Takayama, K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release, 2007, 118(2), 177-184.
29. Liang, J.F.; Yang, V.C.; Vaynshteyn, Y. The minimal functional sequence of protamine. Biochem. Biophys. Res. Commun., 2005, 336(2), 653-659.
30. Kamei, N.; Morishita, M.; Eda, Y.; Ida, N.; Nishio, R.; Takayama, K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release, 2008, 132(1), 21-25.
31. Khafagy, E.S.; Morishita, M. Oral biodrug delivery using cellpenetrating peptide. Adv. Drug Delivery Rev., 2012, 64(6), 531-539.
32. Kamei, N.; Nielsen, E.J.B.; Khafagy, E.S.; Morishita, M. Noninvasive insulin delivery: the great potential of cell-penetrating peptides. Therapeut. Deliv., 2013, 4(3), 315-326.
33. He, H.; Dong, W.; Gong, J.; Wang, J.; Yang, V.C. Developing macromolecular therapeutics: the future drug-of-choice. Front. Chem. Sci. Eng., 2010, 4(1),10-17.
34. Tsumuraya, T.; Matsushita, M. COPA and SLC4A4 are required for cellular entry of arginine-rich peptides. Plos One, 2014, 9(1), e86639.
35. Ziegler, A.; Nervi, P.; Dürrenberger, M.; Seelig, J. The cationic cell-penetrating peptide CPPTAT derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry, 2005, 44(1), 138-148.
36. Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chernomordik, L.V.; Lebleu, B. Cell-penetrating peptides A reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 2003, 278(1), 585-590.
37. Hassane, F.S.; Saleh, A.; Abes, R.; Gait, M.; Lebleu, B. Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell Mol. Life Sci., 2010, 67(5), 715-726.
38. Cermenati, G.; Terracciano, I.; Castelli, I.; Giordana, B.; Rao, R.; Pennacchio, F.; Casartelli, M. The CPP Tat enhances eGFP cell internalization and transepithelial transport by the larval midgut of Bombyx mori (Lepidoptera, Bombycidae). J. Insect. Physiol., 2011, 57(12), 1689-1697.
39. He, H.; Sheng, J.; David, A.E.; Kwon, Y.M.; Zhang, J.; Huang, Y.; Wang, J.; Yang, V.C. The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials, 2013, 34(31), 7733-7743.
40. Liang, J.F.; Yang, V.C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem. Biophys. Res. Commun., 2005, 335(3), 734-738.
41. Patel, L.N.; Wang, J.; Kim, K.J.; Borok, Z.; Crandall, E.D.; Shen, W.C. Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin. Mol. Pharm., 2009, 6(2), 492-503.
42. Byun, Y.; Singh, V.K.; Yang, V.C. Low molecular weight protamine: A potential nontoxic heparin antagonist. Thromb. Res., 1999, 94(1), 53-61.
43. Scott, D.; Fisher, A. The effect of zinc salts on the action of insulin. J. Pharmacol. Exp. Ther., 1935, 55(2), 206-221.
44. Hagedorn, H.; Jensen, B.N.; Krarup, N.; Wodstrup, I. Protamine insulinate. J. Am. Med. Assoc., 1936, 106(3), 177-180.
45. Kerr, R.; Best, C.; Campbell, W.; Fletcher, A. Protamine Insulin. Can. Med. Assoc. J., 1936, 34(4), 400.
46. Tsui, B.; Singh, V.K.; Liang, J.F.; Yang, V.C. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thromb. Res., 2001, 101(5), 417-420.
47. Chang, L.C.; Lee, H.F.; Yang, Z.; Yang, V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): Preparation and characterization. AAPS PharmSci., 2001, 3(3), 7-14.
48. Chang, L.C.; Liang, J.F.; Lee, H.F.; Lee, L.M.; Yang, V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity. AAPS Pharm. Sci., 2001, 3(3), 15-23.
49. Chang, L.C.; Wrobleski, S.; Wakefield, T.W.; Lee, L.M.; Yang, V.C. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci., 2001, 3(3), 24-31.
50. Park, Y.J.; Chang, L.C.; Liang, J.F.; Moon, C.; Chung, C.P.; Yang, V.C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: In vitro and in vivo study. FASEB J., 2005, 19(11), 1555-1557.
51. Kamei, N.; Morishita, M.; Ehara, J.; Takayama, K. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery. J. Control. Release, 2008, 131(2), 94-99.
52. Müller, J.; Triebus, J.; Kretzschmar, I.; Volkmer, R.; Boisguerin, P. The agony of choice: how to find a suitable CPP for cargo delivery. J. Pept. Sci., 2012, 18(5), 293-301.
53. Manosroi, J.; Tangjai, T.; Werner, R.; Götz, F.; Manosroi, W.; Manosroi, A. Potent and prolonged hypoglycemic activity of an oral insulin-Tat mixture in diabetic mice. Drug Res., 2013, 63(7), 351-356.
54. Park, Y.J.; Liang, J.F.; Ko, K.S.; Kim, S.W.; Yang, V.C. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J. Gene Med., 2003, 5(8), 700-711.
55. Choi, Y.S.; Lee, J.Y.; Suh, J.S.; Kwon, Y.M.; Lee, S.J.; Chung, J.K.; Lee, D.S.; Yang, V.C.; Chung, C.P.; Park, Y.J. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials, 2010, 31(6), 1429-1443.
56. He, H.; David, A.E.; Zhang, J.; Park, Y.S.; Wang, J.; Huang, Y.; Wang, J.; Yang, V.C. Low molecular weight protamine/insulin formulation with potential to attenuate protamine-masqueraded insulin allergy. Macromol, Res., 2011, 19(12), 1224-1226.
57. Kamei, N.; Morishita, M.; Takayama, K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Control. Release, 2009, 136(3), 179-186.
58. Zhang, L.; Song, L.; Zhang, C.; Ren, Y. Improving intestinal insulin absorption efficiency through coadministration of cellpenetrating peptide and hydroxypropyl-β-cyclodextrin. Carbohydr. Polym., 2012, 87(2), 1822-1827.
59. Khafagy, E.S.; Morishita, M.; Ida, N.; Nishio, R.; Isowa, K.; Takayama, K. Structural requirements of penetratin absorption enhancement efficiency for insulin delivery. J. Control. Release, 2010, 143(3), 302-310.
60. Khafagy, E.S.; Morishita, M.; Takayama, K. The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int. J. Pharm., 2010, 388(1), 209-212.
61. Kamei, N.; Kikuchi, S.; Morishita, M.; Terasawa, Y.; Yasuda, A.; Yamamoto, S.; Ida, N.; Nishio, R.; Takayama, K. Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps. J. Pharm. Sci., 2013, 102(2), 469-479.
62. Torchilin, V. P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Peptide Sci., 2008, 90(5), 604-610.
63. Bu, X.; Zhu, T.; Ma, Y.; Shen, Q. Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxelloaded nanoparticles. Drug Dev. Ind. Pharm., 2014, 1-8.
64. El-Sayed, A.; Khalil, I.A.; Kogure, K.; Futaki, S.; Harashima, H. Octaarginine-and octalysine-modified nanoparticles have different modes of endosomal escape. J. Biol. Chem., 2008, 283(34), 23450-23461.
65. Koch, A.M.; Reynolds, F.; Merkle, H.P.; Weissleder, R.; Josephson, L. Transport Of Surface-Modified Nanoparticles Through Cell Monolayers. Chembiochem, 2005, 6(2), 337-345.
66. Xia, H.; Gao, X.; Gu, G.; Liu, Z.; Zeng, N.; Hu, Q.; Song, Q.; Yao, L.; Pang, Z.; Jiang, X. Low molecular weight protaminefunctionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials, 2011, 32(36), 9888-9898.
67. Yan, L.; Wang, H.; Jiang, Y.; Liu, J.; Wang, Z.; Yang, Y.; Huang, S.; Huang, Y. Cell-penetrating peptide-modified plga nanoparticles for enhanced nose-to-brain macromolecular delivery. Macromol. Res., 2013, 21(4), 435-441.
68. Liu, X.; Liu, C.; Zhang, W.; Xie, C.; Wei, G.; Lu, W. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int. J. Pharm., 2013, 448(1), 159-167.
69. MuÈller, R.H.; MaÈder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177.
70. Mehnert, W.; Mäder, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47(2), 165-196.
71. Chen, Y.; Yuan, L.; Zhou, L.; Zhang, Z.; Cao, W.; Wu, Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int. J. Nanomedicine, 2011, 7, 4581-4591.
72. Tahara, Y.; Honda, S.; Kamiya, N.; Goto, M. Transdermal delivery of insulin using a solid-in-oil nanodispersion enhanced by argininerich peptides. Med. Chem. Comm., 2012, 3(12), 1496-1499.
73. Ohtake, K.; Maeno, T.; Ueda, H.; Natsume, H.; Morimoto, Y. Poly- L-arginine predominantly increases the paracellular permeability of hydrophilic macromolecules across rabbit nasal epithelium in vitro. Pharm. Res., 2003, 20(2), 153-160.
74. Hussain, F.; Hojjati, M.; Okamoto, M.; Gorga, R.E. Review article: polymer-matrix nanocomposites, processing, manufacturing, and application: An overview. J. Compos. Mater., 2006, 40(17), 1511-1575.
75. Malhotra, M.; Tomaro-Duchesneau, C.; Prakash, S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials, 2013, 34(4), 1270-1280.
76. Zhu, X.; Shan, W.; Zhang, P.; Jin, Y.; Guan, S.; Fan, T.; Yang, Y.; Zhou, Z.; Huang, Y. Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery. Mol. Pharm., 2013, 11(1), 317-328.
77. Sun, V.Z.; Li, Z.; Deming, T.J.; Kamei, D.T. Intracellular fates of cell-penetrating block copolypeptide vesicles. Biomacromolecules, 2010, 12(1), 10-13.
78. Nemoto, E.; Takahashi, H.; Kobayashi, D.; Ueda, H.; Morimoto, Y. Effects of poly-L-arginine on the permeation of hydrophilic compounds through surface ocular tissues. Biol. Pharm. Bull., 2006, 29(1), 155-160.
79. Seki, T.; Kanbayashi, H.; Chono, S.; Tabata, Y.; Morimoto, K. Effects of a sperminated gelatin on the nasal absorption of insulin. Int. J. Pharm., 2007, 338(1), 213-218.
80. Seki, T.; Fukushi, N.; Chono, S.; Morimoto, K. Effects of sperminated polymers on the pulmonary absorption of insulin. J. Control. Release, 2008, 125(3), 246-251.
81. Sakuma S.; Suita M.; Inoue S.; Marui Y.; Nishida K.; Masaoka Y.; Kataoka M.; Yamashita S.; Nakajima N.; Shinkai N. Cellpenetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Mol. Pharm., 2012, 9(10), 2933-2941.
82. Sakuma, S.; Suita, M.; Masaoka, Y.; Kataoka, M.; Nakajima, N.; Shinkai, N.; Yamauchi, H.; Hiwatari, K.I.; Tachikawa, H.; Kimura, R. Oligoarginine-linked polymers as a new class of penetration enhancers. J. Control. Release, 2010, 148(2), 187-196.
83. Sakuma, S.; Suita, M.; Yamamoto, T.; Masaoka, Y.; Kataoka, M.; Yamashita, S.; Nakajima, N.; Shinkai, N.; Yamauchi, H.; Hiwatari, K.I. Performance of cell-penetrating peptide-linked polymers physically mixed with poorly membrane-permeable molecules on cell membranes. Eur. J. Pharm. Biopharm., 2012, 81(1), 64-73.
84. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2012, 64, 206-212.
85. Lee, H.J.; Pardridge, W.M. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug. Chem., 2001, 12(6), 995-999.
86. Kamei, N.; Morishita, M.; Kanayama, Y.; Hasegawa, K.; Nishimura, M.; Hayashinaka, E.; Wada, Y.; Watanabe, Y.; Takayama, K. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography. J. Control. Release, 2010, 146(1), 16-22.
87. Amantana, A.; Moulton, H.M.; Cate M.L.; Reddy, M.T.; Whitehead, T.; Hassinger, J.N.; Youngblood, D.S.; Iversen, P.L. Pharmacokinetics, biodistribution, stability and toxicity of a cellpenetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem., 2007, 18(4), 1325-1331.
88. Bertrand, N.; Leroux, J.C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Release, 2012, 161(2), 152-163.
89. Lebleu, B.; Moulton, H.M.; Abes, R.; Ivanova, G.D.; Abes, S.; Stein, D.A.; Iversen, P.L.; Arzumanov, A.A.; Gait, M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Delivery Rev., 2008, 60(4), 517-529.
90. Gu, G.; Xia, H.; Hu, Q.; Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Tu, Y.; Pang, Z.; Song, Q. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials, 2013, 34(1), 196-208.
91. Hayashi, Y.; Yamauchi, J.; Khalil, I.A.; Kajimoto, K.; Akita, H.; Harashima, H. Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int. J. Pharm., 2011, 419(1), 308-313.
92. Khafagy, E.S.; Kamei, N.; Nielsen, E.J.B.; Nishio, R.; Morishita, M. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats. Eur. J. Pharm. Biopharm., 2013, 85(3), 736-743.
93. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 1997, 272(25), 16010-16017.
94. Ghazavi, M.K.; Johnston, G.A. Insulin allergy. Clin. Dermatol., 2011, 29(3), 300-305.
95. Torosantucci, R.; Brinks, V.; Kijanka, G.; Halim, L.A.; Sauerborn, M.; Schellekens, H.; Jiskoot, W. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. J. Pharm. Sci., 2014, 103(5), 1367-1374.
96. Yang, C.; Lu, D.; Liu, Z. How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry, 2011, 50(13), 2585-2593.
97. Khafagy, E.S.; Morishita, M.; Kamei, N.; Eda, Y.; Ikeno, Y.; Takayama, K. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm., 2009, 381(1), 49-55.
98. Liu, X.; Zhang, W.; Wei, G.; Lu, W. [Poly (arginine) 8 enhanced intestinal absorption of insulin-loaded nanoparticles]. Yao xue xue bao= Acta. Pharmaceutica. Sinica., 2012, 47(4), 512-516.
99. Friedman, M. Formation, nutritional value, and safety of D-amino acids. Adv. Exp. Med. Biol., 1991, 289, 447-481.
100. He, H.; Ye, J.; Sheng, J.; Wang, J.; Huang, Y.; Chen, G.; Wang, J.; Yang, V.C. Overcoming oral insulin delivery barriers: application of cell penetrating peptide and silica-based nanoporous composites. Front. Chem. Sci. Eng., 2013, 7(1), 9-19.
101. Frankel, A.D.; Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55(6), 1189-1193.
102. Kumar, S.; Sahdev, P.; Perumal, O.; Tummala, H. Identification of a novel skin penetration enhancement peptide by phage display peptide library screening. Mol. Pharm., 2012, 9(5), 1320-1330.